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Background
Genetic diversity is a major challenge in the design of
vaccines against variable viruses, including HIV. Engineer-
ing vaccines to induce immune responses that preferen-
tially target conserved antigenic regions could thus
contribute to improved HIV vaccines.
Methods
During the Tanzania Mozambique HIV Vaccine trial
(TaMoVac 01) phase 2a HIV vaccine trial, HIV negative
Tanzanian volunteers received 3x 0.6 or 1mg intradermal
injections with a multiclade, multigene DNA vaccine that
included 2 plasmids encoding for clade B Gag-p37 (p17 &
p24) and a recombinant Gag-p37 (clade B p17 & clade A
p24). DNA vaccine recipients were boosted with Modified
Vaccinia Ankara (MVA)-CMDR expressing clade A Gag
that additionally covered the Gag-p15 region. Vaccine-
induced T cell responses were characterized using IFN-
gamma ELISpot in 45 participants after stimulation of
fresh PBMC with 9 peptide pools subdividing Gag into 9
distinct antigenic regions. Data were analyzed using the
Mann-Whitney test and linear regression analysis.
Results
Antigenic regions p17 and p24 included in the DNA
prime and the MVA boost were recognized with higher
median magnitude than antigenic regions within p15,
which was only covered by the MVA boost (p<0.0001).
Antigenic regions within p24 (clade A&B prime and clade
A boost) were better recognized than those within p17
(clade B prime and clade A boost; p<0.0001). We then
determined the sequence homology between the MVA
and the DNA Gag vaccine immunogens for each of the
peptide pools. The sequence homology ranged between
91% and 0% (for p15) of total amino acids within a given
peptide pool and there was a linear correlation between
the sequence homology and the response rate (p=0.04,
r2=0.47).
Conclusion
These preliminary results support the hypothesis that het-
erologous prime-boost vaccine regimens preferentially
induce immune responses targeting regions that are con-
served between the priming and boosting vaccines.
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